<DOC>
	<DOCNO>NCT02491047</DOCNO>
	<brief_summary>This prospective , multi-national , multicenter , randomize , two arm , single blind , Standard Care ( SOC ) control , blind central reading center study . This study assess safety performance BonyPid-1000™ severe open tibial fracture ( Gustilo IIIA IIIB ) implant adjunct SOC compare SOC alone .</brief_summary>
	<brief_title>Safety Performance BonyPid-1000™ Treatment Gustilo IIIA IIIB Tibial Open Fractures</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Tibial Fractures</mesh_term>
	<mesh_term>Fractures , Open</mesh_term>
	<criteria>1 . Male nonpregnant female age ≥ 18 year ≤70 year . 2 . Subjects tibia open fracture Gustilo grade , IIIA IIIB 3 . Multiinjured subject hemodynamically physiologically stable 4 . Subjects able willing sign inform consent form , prior protocolspecific procedure perform accept comply protocol requirement duration study . 1 . Female pregnant breastfeeding . 2 . Subjects know current disseminated malignancy , active cancer autoimmune disease . 3 . Subjects fracture due know medical history Osteoporosis . 4 . Diabetic subject drug insulin dependent . 5 . Heavy smoker last 6 month . 6 . Nonambulating subject prior trauma . 7 . Subjects admit Emergency Room ( ER ) 24 hour ( &gt; 24h ) post injury . 8 . Subjects bone fracture due know medical history metabolic bone disease . 9 . Subjects hypersensitivity doxycycline tetracycline family drug . 10 . Subjects treat systemic doxycycline last 4 week prior screen . 11 . Previous surgical intervention target fracture site . 12 . Subjects currently receive receive investigational product last 30 day and/or participate another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>